CINECA IRIS Institutional Research Information System

BRANCACCIO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.903
NA - Nord America 853
SA - Sud America 696
EU - Europa 316
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 40
OC - Oceania 3
Totale 3.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 800
BR - Brasile 542
HK - Hong Kong 499
SG - Singapore 431
VN - Vietnam 314
CN - Cina 218
KR - Corea 196
BD - Bangladesh 162
IT - Italia 149
AR - Argentina 65
DE - Germania 50
FR - Francia 37
EC - Ecuador 35
ID - Indonesia 31
GB - Regno Unito 20
RU - Federazione Russa 20
MX - Messico 18
CO - Colombia 17
CA - Canada 16
ZA - Sudafrica 16
PY - Paraguay 13
PL - Polonia 12
IN - India 11
CL - Cile 10
IQ - Iraq 9
JM - Giamaica 7
UA - Ucraina 7
EG - Egitto 6
MA - Marocco 6
NL - Olanda 6
UZ - Uzbekistan 6
VE - Venezuela 6
NP - Nepal 5
DZ - Algeria 4
SV - El Salvador 4
AU - Australia 3
CR - Costa Rica 3
ES - Italia 3
GT - Guatemala 3
IL - Israele 3
PK - Pakistan 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
IR - Iran 2
JP - Giappone 2
KE - Kenya 2
PE - Perù 2
RS - Serbia 2
SA - Arabia Saudita 2
TN - Tunisia 2
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
ET - Etiopia 1
FI - Finlandia 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
KZ - Kazakistan 1
LB - Libano 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SE - Svezia 1
SN - Senegal 1
TG - Togo 1
TR - Turchia 1
Totale 3.811
Salva come PNG Salva come JPEG
Città #
Hong Kong 498
San Jose 258
Seoul 196
Singapore 160
Ho Chi Minh City 111
Ashburn 98
Chicago 74
Hanoi 65
Beijing 49
Frankfurt am Main 44
São Paulo 44
New York 27
Santa Clara 24
Dallas 21
Haiphong 19
Sona 19
Da Nang 18
Rio de Janeiro 16
Mexico City 13
Hillsboro 12
Buffalo 11
Guayaquil 11
Los Angeles 11
Milan 11
Belo Horizonte 10
Biên Hòa 10
Quito 10
Manaus 9
Padua 9
Brasília 8
Curitiba 8
Naples 8
Phoenix 8
Porto Alegre 8
Rome 8
Warsaw 8
Buenos Aires 7
Bari 6
Campinas 6
Florence 6
Fortaleza 6
Goiânia 6
Hải Dương 6
Piscataway 6
Quảng Ngãi 6
Tashkent 6
Asunción 5
Boardman 5
Jacksonville 5
Johannesburg 5
Ninh Bình 5
Osasco 5
Palermo 5
Phủ Lý 5
Piracicaba 5
Santo André 5
Sumaré 5
Bauru 4
Bogotá 4
Bologna 4
Bragança Paulista 4
Can Tho 4
Casablanca 4
Council Bluffs 4
Franca 4
Guarulhos 4
Ha Long 4
Houston 4
Joinville 4
Macaé 4
Orem 4
Recife 4
Roubaix 4
Salvador 4
São Gonçalo 4
Turin 4
Wroclaw 4
Amsterdam 3
Bandung 3
Belford Roxo 3
Brooklyn 3
Cairo 3
Campina Grande 3
Cape Town 3
Caracas 3
Catania 3
Caxias do Sul 3
Chapecó 3
Charlotte 3
Criciúma 3
Dhaka 3
Florianópolis 3
Formosa 3
Hortolândia 3
Huế 3
Ibirité 3
Itaquaquecetuba 3
Jakarta 3
Juiz de Fora 3
Limburg an der Lahn 3
Totale 2.179
Salva come PNG Salva come JPEG
Nome #
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 90
An increase in the levels of middle surface antigen characterizes patients developing hbv-driven liver cancer despite prolonged virological suppression 83
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 68
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 63
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 62
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 59
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 57
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 56
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 56
AISF position paper on HCV in immunocompromised patients 56
Virological patterns of HCV patients with failure to interferon-free regimens 55
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 52
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 52
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 52
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 51
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 49
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 48
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 48
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years 48
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis 47
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 47
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 47
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 46
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 45
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 45
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 45
Prophylaxis of hepatitis B virus (HBV) re-infection in liver transplantation: Is the reappearance of hepatitis B surface antigen (HBsAg) significant? 44
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 43
Recent breakthroughs in the treatment of chronic hepatitis Delta 42
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 42
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 42
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply 40
CD8+ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis 40
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 40
null 40
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare 39
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 39
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 39
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 39
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 39
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency 38
Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants 38
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma 37
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues 37
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 36
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 36
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 36
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 36
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 +  35
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 35
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 35
Hepatitis c late relapse in patients with directly acting antiviral- related sustained virological response at week 12 35
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications 35
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 35
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 35
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 35
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 34
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues 34
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 34
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 34
Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with Peg-Interferon and Ribavirin 34
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 33
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 33
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 33
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 33
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 33
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 32
Association between sustained virological response and adverse liver-related events in patients with decompensated HCV cirrhosis 31
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 31
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 31
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 31
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy 31
Liver transplantation for t2 hepatocellular carcinoma during the covid-19 pandemic: A novel model balancing individual benefit against healthcare resources 31
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 30
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 30
Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays 30
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 30
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 30
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 30
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 30
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 29
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 29
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 29
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 29
Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions 29
Hepatitis delta infection in Italian patients: towards the end of the story? 29
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 29
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 29
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 27
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 27
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 27
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 26
Letter Comment to: Which saint to pray for fighting against COVID? A short survey. By Perciaccante A et al 26
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 26
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study 25
Hepatitis C Virus Clearance in Older Adults 25
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 24
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 24
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 23
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 21
Totale 3.865
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.706
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.706
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025859 0 0 0 0 0 0 0 0 137 492 208 22
2025/20262.853 155 97 498 666 211 53 28 409 211 134 238 153
2026/2027205 44 139 20 2 0 0 0 0 0 0 0 0
Totale 3.917